Virofree

Virofree Limited is a UK based company focused on the development, manufacture, and distribution of anti-pathogenic technologies and medical devices. Our first commercial product line consists of a novel, highly effective, anti-viral facemask.

In the absence of an effective vaccines or other effective medication, the use of antiviral / pathogenic protection may become imperative. Our vision is to help minimise the harmful effects of pathogens on humans, animals, world economies, and the environment.

Recent market statistics estimate the current global market is worth approx. $74.9 billion with a growth rate of 53% (CAGR), with an estimated, global demand of 80 million marks per day.

To meet demand, Virofree has successfully developed a coating process that allows the mass production of anti-viral face-masks. Our face-masks can trap and kill pathogenic viruses, such asSARS-CoV-2 (responsible for COVID-19), H1N1, H5N1, H7N9 influenza, RSV, and bacteria like S.aureus and tuberculosis.

Importantly, our masks outperform comparable masks without Virofree technology (as tested with aero-biology protocols). Such efficacy reflects the immense benefits to the actual wearer. In our opinion competitor masks are not tested so rigorously (if tested at all) and only tested with liquid drops of pathogen laid on the surface. Such testing protocols have limited relevance to real-life usage. They are also not very effective in testing for how many airborne viruses are escaping the filtration mechanism, and thus the level of protection offered.

Manufacturing production of Virofree anti-viral masks is a key competitive edge for us, and a critical success factor. We have designed, a streamlined, highly efficient, cost-competitive, resource optimized implementation plan that cannot be easily matched by existing suppliers.

Company’s Keywords:

medical devices, ffp3, mask, antiviral technologies, antiviral, filters, antipathogen, n95